NEWS

Press Releases

Media Coverage

Additional Partnerships

For all media inquiries, please contact media@tempus.com

06/01/2021
Tempus Announces Eleven Abstracts Accepted for Presentation at the 2021 American Society of Clinical Oncology Annual Meeting

Tempus, a leader in artificial intelligence and precision medicine, today announced eleven abstracts accepted for presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place virtually from June 4 - 8. “These high impact ASCO presentations from Tempus collaborators and investigators illustrate the power of over 35 pe...
05/20/2021
- Clinical Trials
- Product Launch
Tempus Unveils Its Lens Platform, Offering Unparalleled Access to One of the World’s Largest De-Identified Clinical and Molecular Datasets

Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of its cloud-based data and analytics platform, Lens. The all-in-one platform will provide scientists and researchers across biotechnology and pharmaceutical companies with short term, on demand access to more than 35 petabytes of de-identified cli...
05/19/2021
- Clinical Trials
- Product Launch
Leading Real-World Data and Analytics Organizations Form Industry Coalition to Advance Policies to Support Regulatory Use of Real-World Evidence

Five real-world data (RWD) and analytics organizations today announced an industry coalition dedicated to advancing the use of real-world evidence (RWE) to support regulatory decisions. Founding members of the RWE Alliance are Aetion, Flatiron Health, IQVIA, Syapse, and Tempus. The RWE Alliance intends t...
04/19/2021

Study Confirms That Americans Neglected Their Healthcare During COVID-19 Pandemic

From the beginning of the pandemic, health experts were concerned that millions of Americans would defer treatment of existing illnesses—including cancer—and postpone routine preventative screenings given the justifiable fear of contracting COVID-19. Now, more than a year after COVID-19 forced the country to a complete halt, a clearer picture is starting to eme...
04/07/2021
- Genomic Sequencing
- Liquid Biopsy
Tempus Announces Abstracts to be Presented at the American Association for Cancer Research Annual Meeting 2021

Tempus, a leader in artificial intelligence and precision medicine, today announced abstracts accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will convene virtually on April 10-15 and May 17-21. The research leverages Tempus’ unparalleled library of multi-modal data to facilitate discovery, development, and delivery of opt...
03/31/2021
- Product Launch
Tempus Launches COVID-19 Test with At Home Sample Collection and COVID-19 Next Generation Sequencing

Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of the Tempus iC Home Collection (1), a COVID-19 test with unsupervised self-collection at home. Physicians can now order the Tempus iC Home Collection test for eligible patients and have the collection kits shipped to their homes for unsupervised self-collection at...
03/24/2021
- Clinical Trials
FDA Grants Breakthrough Device Designation To Tempus’ Atrial Fibrillation ECG Analysis Platform, Developed in Collaboration With Geisinger

Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its ECG Analysis Platform. The platform, developed in collaboration with Geisinger, aids clinicians in identifying patients at increased risk of developing atr...
03/15/2021
- Clinical Trials
- Genomic Sequencing
Community Health Network Collaborates with Tempus to Personalize Cancer Care, Improve Patient Health Through Genomics Testing

Community Health Network announced today it is collaborating with Tempus, a leader in precision medicine and artificial intelligence, to improve patient health and outcomes through genomic testing. Among a variety of precision medicine solutions, Tempus offers a suite of oncology-focused genomic testing and targeted clinical trial matching. The...
03/05/2021
- Cardiology
- Clinical Trials
Researchers Find AI Can Predict New Atrial Fibrillation, Stroke Risk

A team of scientists from Geisinger and Tempus have found that artificial intelligence can predict risk of new atrial fibrillation (AF) and AF-related stroke. Atrial fibrillation is the most common cardiac arrhythmia and is associated with numerous health risks, including stroke and death. The study, published in Circulation, used el...
02/25/2021
Tempus Announces Sequencing and Computational Biology Collaboration with Kronos Bio to Support the Development of CDK9 Inhibitor KB-0742

Tempus, a leader in artificial intelligence and precision medicine, today announced a collaboration with Kronos Bio, Inc., to perform sequencing analysis for patients enrolled in Kronos Bio’s Phase 1/2 clinical trial of KB-0742, the company’s investigational CDK9 inhibitor. Tempus will use its xT broad-panel genomic assay to provide retrospective sequenc...

20 21 22